Efalizumab-induced bullous pemphigoid.
Duong
Tu Anh
TA
Department of Dermatology, Hôpital Henri Mondor, Université Paris, Créteil, France. Electronic address: tu-anh.duong@hmn.aphp.fr.
Buffard
Valérie
V
Department of Dermatology, Hôpital Henri Mondor, Université Paris, Créteil, France.
André
Chantal
C
Department of Immunology, Hôpital Henri Mondor, Université Paris, Créteil, France.
Ortonne
Nicolas
N
Department of Pathology, Hôpital Henri Mondor, Université Paris, Créteil, France.
Revuz
Jean
J
Department of Dermatology, Hôpital Henri Mondor, Université Paris, Créteil, France.
Bagot
Martine
M
Department of Dermatology, Hôpital Henri Mondor, Université Paris, Créteil, France.
Roujeau
Jean-Claude
JC
Department of Dermatology, Hôpital Henri Mondor, Université Paris, Créteil, France.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D018845:CD11 Antigens / Q000008:administration & dosage / Q000009:adverse effects*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010391:Pemphigoid, Bullous / Q000139:chemically induced* / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018845:CD11 Antigens; D005938:Glucocorticoids; C472181:efalizumab